Sign in
RLYB Stock Price, Chart, Stats & News
Rallybio Corporation
Save
91.12M
Market cap
–
Current P/E
–
Forward P/E
RLYB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.65% |
Operating margin | -3853.61% |
Pretax margin | -1046.39% |
Net margin | -1046.39% |
Effective tax rate | – |
ROA | -14.42% |
ROE | -16.25% |
D/E | 0.00x |
Interest coverage ratio | – |
RLYB valuation
P/E | – |
P/S | 50.68x |
P/B | 0.75x |
P/CF | -1.46x |
P/FCF | -1.46x |
P/OCF | -1.46x |
PEG | -0.14x |
EV multiple | -2.26x |
About
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Similar securities
Based on sector and market capitalization
Report issue